Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 6, 2009, Pages 605-608

  Birkenfeld, A L ^a   Jordan, J ^b   Hofmann, U ^c   Busjahn, A ^d   Franke, G ^a   Kruger N ^a   Igel, S ^c   Murdter T ^c   Drescher, S ^c,e   Shi, S ^c,f   Engeli, S ^b   Schwab, M ^c,g   Eichelbaum, M ^c   Luft, F C ^a   Fromm, M F ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d HealthTwist GmbH   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GLYCOPROTEIN P;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; FEMALE; GENETIC VARIABILITY; HEREDITY; HUMAN; HUMAN EXPERIMENT; MALE; MONOZYGOTIC TWINS; NORMAL HUMAN; PHARMACOGENETICS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; DEUTERIUM; DIGOXIN; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; P-GLYCOPROTEIN; PHENOTYPE; PILOT PROJECTS; REGISTRIES; TWINS, MONOZYGOTIC; YOUNG ADULT;

EID: 70450253101     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.170     Document Type: Article

References (30)

1. Custodio, J.M., Wu, C.Y. & Benet, L.Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 60, 717-733 (2008).
2. Fenner, K.S. et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85, 173-181 (2009).
3. Fromm, M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423-429 (2004).
4. Ho, R.H. & Kim, R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78, 260-277 (2005).
5. Igel, S. et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efux. Clin. Pharmacokinet. 46, 777-785 (2007).
6. Lown, K.S. et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248-260 (1997).
7. Berggren, S. et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm. 4, 252-257 (2007).
8. Mouly, S. & Paine, M.F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res. 20, 1595-1599 (2003).
9. von Richter, O., Burk, O., Fromm, M.F., Thon, K.P., Eichelbaum, M. & Kivistö, K.T. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther. 75, 172-183 (2004).
10. Lown, K.S. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99, 2545-2553 (1997).
11. Fontana, R.J. et al. Efects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 117, 89-98 (1999).
12. Giessmann, T. et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and infuences disposition of talinolol in humans. Clin. Pharmacol. Ther. 76, 192-200 (2004).
13. Greiner, B. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153 (1999).
14. Paine, M.F. et al. Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am. J. Clin. Nutr. 87, 863-871 (2008).
15. Hofmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 3473-3478 (2000).
16. Kim, R.B. et al. Identifcation of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199 (2001).
17. Maeda, K. & Sugiyama, Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 23, 223-235 (2008).
18. Marzolini, C., Paus, E., Buclin, T. & Kim, R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33 (2004).
19. Schwab, M., Eichelbaum, M. & Fromm, M.F. Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307 (2003). (Pubitemid 37372643)
20. Becquemont, L. et al. Efects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin. Pharmacol. Ther. 79, 449-460 (2006).
21. Hebert, M.F. et al. Efects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin. Pharmacol. Ther. 84, 248-253 (2008).
22. Kroetz, D.L. et al. Heritability of digoxin pharmacokinetics. Clin. Pharmacol. Ther. 77, P21 (2005) [abstract].
23. Alexanderson, B., Evans, D.A. & Sjöqvist, F. Steady-state plasma levels of nortriptyline in twins: infuence of genetic factors and drug therapy. Br. Med. J. 4, 764-768 (1969).
24. Jordan, J. et al. Heritability of free and receptor-bound leptin in normal twins. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R1411-R1416 (2005).
25. Rasmussen, B.B., Brix, T.H., Kyvik, K.O. & Brøsen, K. The interindividual diferences in the 3-demethylation of cafeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12, 473-478 (2002).
26. Kalow, W., Tang, B.K. & Endrenyi, L. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8, 283-289 (1998).
27. Heck, H.A. et al. Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests. J. Pharmacokinet. Biopharm. 7, 233-248 (1979).
28. Kullak-Ublick, G.A. et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120, 525-533 (2001).
29. Kimchi-Sarfaty, C. et al. A "silent" polymorphism in the MDR1 gene changes substrate specifcity. Science 315, 525-528 (2007). (Pubitemid 46175758)
30. Wang, D., Johnson, A.D., Papp, A.C., Kroetz, D.L. & Sadée, W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C T afects mRNA stability. Pharmacogenet. Genomics 15, 693-704 (2005).